Industry to Meet as MHRA, the Dutch Healthcare Inspectorate and the PDA Join 30 Industry Leaders Sharing their Views on Innovation in Clinical Trial Supply Practice and Regulations
In the wake of a transformed pharmaceutical market due to mergers and acquisitions, industry leaders are to converge in Rotterdam on 27th-28th January 2011, to discuss the latest push in cost cutting and supply stock out mitigation.
Originally initiated in 2007, the official amendments, released by the European Union, come into force on 21 March 2010, in an effort to bring about a more regulated environment for medical devices in Europe not only when gaining CE approval but for safety reporting requirements also.
Pharmaceutical giants such as GlaxoSmithKline, Merck and Boehringer Ingelheim are meeting in January at Pharma IQ's Clinical Trial Supply Europe 2011 Conference to discuss these recent developments and share information on the latest strategies, technology and techniques being employed by leaders of the field to ensure continued process improvement in a recovering financial climate.
In a recent podcast for Pharma IQ, Steve Jacobs President at Global Clinical Supplies Group declared: "Whereas we used to wind up wasting 20-50% of clinical supplies made, the industry is now trying to come up with ways where we can deliver clinical supplies, get the patient in and the study done as fast as possible in a cost reasonable way […]. We all want to know the things we can do to make ourselves more successful. Going to a conference like this is going to allow you to go back to your company a little smarter, with a little bit more experience. […] That is the kind of stuff this conference will be able to give you".
For more information about the upcoming Clinical Trial Supply Europe 2011 Conference visit http://www.clinicalmedicaldevice.com/ or phone + 44 (0) 20 7368 93.
Media contact: Hinde Liepmannsohn, Marketing Manager, Pharma IQ/IQPCPh: 0207 368 9774 or email firstname.lastname@example.org.